BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32974985)

  • 21. Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors.
    Ma D; Nutt CL; Shanehsaz P; Peng X; Louis DN; Kaetzel DM
    Cancer Res; 2005 Jul; 65(13):5523-34. PubMed ID: 15994924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.
    Lin CA; Rhodes CT; Lin C; Phillips JJ; Berger MS
    Cell Cycle; 2017 Apr; 16(8):765-775. PubMed ID: 28278055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of glioblastoma (GBM) molecular classification methods.
    Lee E; Yong RL; Paddison P; Zhu J
    Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayesian nonlinear model selection for gene regulatory networks.
    Ni Y; Stingo FC; Baladandayuthapani V
    Biometrics; 2015 Sep; 71(3):585-95. PubMed ID: 25854759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification.
    Li B; Senbabaoglu Y; Peng W; Yang ML; Xu J; Li JZ
    Clin Cancer Res; 2012 Oct; 18(20):5595-605. PubMed ID: 22912392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SYGNALing a Red Light for Glioblastoma.
    Brooks AN; Mueller WF; Steinmetz LM
    Cell Syst; 2016 Aug; 3(2):118-120. PubMed ID: 27559923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.
    Teng J; da Hora CC; Kantar RS; Nakano I; Wakimoto H; Batchelor TT; Chiocca EA; Badr CE; Tannous BA
    Neuro Oncol; 2017 Jun; 19(6):820-832. PubMed ID: 28062830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Crucial Candidate Genes and Pathways in Glioblastoma Multiform by Bioinformatics Analysis.
    Alshabi AM; Vastrad B; Shaikh IA; Vastrad C
    Biomolecules; 2019 May; 9(5):. PubMed ID: 31137733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations.
    Teo WY; Sekar K; Seshachalam P; Shen J; Chow WY; Lau CC; Yang H; Park J; Kang SG; Li X; Nam DH; Hui KM
    Sci Rep; 2019 May; 9(1):7442. PubMed ID: 31092847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison and analysis of lncRNA-mediated ceRNA regulation in different molecular subtypes of glioblastoma.
    Li Q; Yu Q; Ji J; Wang P; Li D
    Mol Omics; 2019 Dec; 15(6):406-419. PubMed ID: 31584593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.
    Genovese G; Ergun A; Shukla SA; Campos B; Hanna J; Ghosh P; Quayle SN; Rai K; Colla S; Ying H; Wu CJ; Sarkar S; Xiao Y; Zhang J; Zhang H; Kwong L; Dunn K; Wiedemeyer WR; Brennan C; Zheng H; Rimm DL; Collins JJ; Chin L
    Cancer Discov; 2012 Aug; 2(8):736-49. PubMed ID: 22750848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.
    Doucette T; Rao G; Rao A; Shen L; Aldape K; Wei J; Dziurzynski K; Gilbert M; Heimberger AB
    Cancer Immunol Res; 2013 Aug; 1(2):112-22. PubMed ID: 24409449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme.
    Heiland DH; Gaebelein A; Börries M; Wörner J; Pompe N; Franco P; Heynckes S; Bartholomae M; hAilín DÓ; Carro MS; Prinz M; Weber S; Mader I; Delev D; Schnell O
    Mol Cancer Res; 2018 Apr; 16(4):655-668. PubMed ID: 29330292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kernel Differential Subgraph Analysis to Reveal the Key Period Affecting Glioblastoma.
    Xie J; Sun J; Feng J; Yang F; Wang J; Wen T; Nie Q
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32079293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the potential oncogenes in glioblastoma based on bioinformatic analysis and elucidation of the underlying mechanisms.
    Zhang Y; Xia Q; Lin J
    Oncol Rep; 2018 Aug; 40(2):715-725. PubMed ID: 29901201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
    He X; Zhang S; Chen J; Li D
    Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
    Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
    Front Immunol; 2021; 12():706936. PubMed ID: 34899682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures.
    Daniel PM; Filiz G; Tymms MJ; Ramsay RG; Kaye AH; Stylli SS; Mantamadiotis T
    Exp Mol Pathol; 2018 Aug; 105(1):23-31. PubMed ID: 29852183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
    Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
    Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Core Regulatory Circuit in Glioblastoma Stem Cells Links MAPK Activation to a Transcriptional Program of Neural Stem Cell Identity.
    Riddick G; Kotliarova S; Rodriguez V; Kim HS; Linkous A; Storaska AJ; Ahn S; Walling J; Belova G; Fine HA
    Sci Rep; 2017 Mar; 7():43605. PubMed ID: 28256619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.